SKYRIZI is the first IL-23 specific inhibitor approved for both moderate to severe ulcerative colitis and moderate to severe Crohn's disease.1 MONTREAL, March 4, 2025 /CNW/ - AbbVie (NYSE: ABBV ...

AbbVie Q4 adjusted EPS of $2.16 beat estimates, with strong sales of Skyrizi (+57.9%) and Rinvoq (+47.1%) boosting revenue growth. AbbVie raises 2027 revenue forecast for Skyrizi and Rinvoq to $31 ...

Skyrizi (risankizumab-rzaa) is a prescription drug used to treat certain autoimmune conditions, including plaque psoriasis and Crohn’s disease. It works by attaching to specific proteins in your ...

Recently, the board selected six brand name drugs for cost review out of a list of hundreds. Skyrizi pen boxes are shown, July 1, 2023, in Houston.

The first step in the plan is an in-depth review of drugs to determine if they cause affordability challenges for Marylanders on state-run health insurance plans. Recently, the board selected six ...

Learn about dosage, side effects, and more of Skyrizi (risankizumab-rzaa), which is a prescription injection used to treat plaque psoriasis.

Skyrizi was the top Rx and over-the-counter (OTC) pharma brand during July, according to data released by iSpot.tv on Monday afternoon. Skyrizi recorded an impressions share of voice (SOV) of 5.18%, ...

Despite the enthusiasm around AbbVie’s fast-rising up-and-coming blockbuster Skyrizi, Entyvio's growth “continues to outperform” the overall IBD market, according to Takeda's recent investor ...

The FDA has given its okay to the biologic drug Skyrizi (risankizumab) as a treatment for people with moderately to severely active ulcerative colitis. The medication works by blocking the immune ...

SKYRIZI (risankizumab-rzaa) is available in a 150 mg/mL prefilled syringe and pen, a 600 mg/10 mL vial for intravenous infusion, and a 180 mg/1.2 mL or 360 mg/2.4 mL single-dose prefilled ...